Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why
11:18am, Tuesday, 05'th Sep 2023
While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help r
Better Buy: Biogen vs. Eli Lilly
10:07am, Tuesday, 29'th Aug 2023
Biogen is adding new products to its lineup to reverse its recent revenue decreases. Eli Lilly has a solid portfolio and strong pipeline, and pays a consistent dividend.
Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment
06:07pm, Thursday, 24'th Aug 2023
Biogen Inc. BIIB, -0.90% shares slipped in the extended session Thursday after the Food and Drug Administration granted a soon-to-be Novartis AG NVS, -1.94% spinoff approval for the first biosimilar t
With an Acquisition on the Way, Is Biogen Stock a Buy?
08:30am, Wednesday, 09'th Aug 2023
Biogen's planned acquisition will add an important product to its portfolio. The company's new Alzheimer's treatment should help it return to growth, too.
FDA approves first postpartum depression pill from Biogen, Sage
10:37am, Monday, 07'th Aug 2023
Yahoo Finance Health care reporter Anjalee Khemlani reports on the FDA approving Zurzuvae which is the first pill to treat postpartum depression.
Biogen, Sage face uphill battle with postpartum depression pill
07:39am, Monday, 07'th Aug 2023
The U.S. drug regulator's approval of Biogen and Sage Therapeutics' first-of-its-kind postpartum depression (PPD) pill is unlikely to allay the drugmakers' growth concerns, analysts said on Monday.
FDA approves first-ever pill for postpartum depression in new mothers
07:40pm, Friday, 04'th Aug 2023
The Food and Drug Administration late Friday approved the first-ever pill that can be taken at home for postpartum depression.
US FDA approves Biogen-Sage Therapeutics pill for clinical depression
07:11pm, Friday, 04'th Aug 2023
The U.S. Food and Drug Administration on Friday approved Biogen and Sage Therapeutics' oral pill for two common forms of depression, paving the way for patients to get a faster-acting therapy to treat
3 ‘Strong Buy' Biotech Stocks You Should Be Loading Up On Now
03:17pm, Wednesday, 02'nd Aug 2023
Medical stocks, in general, aren't enjoying the market-wide reversal we're seeing in the back half of 2023. The Morningstar US Healthcare Index, which measures a range of biotech, pharma, medical devi
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
02:59pm, Tuesday, 01'st Aug 2023
The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%.
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
05:45am, Tuesday, 01'st Aug 2023
Biogen's revenue has been on the decline as the company relies on older products that are losing exclusivity. The acquisition of Reata Pharmaceuticals offers Biogen a new product that could help drive
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
07:45am, Monday, 31'st Jul 2023
Biogen and Eli Lilly are two major competitors in the field of Alzheimer's disease. Eli Lilly's medicine appears to slow the rate of cognitive decline more than Biogen's.
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
09:08am, Saturday, 29'th Jul 2023
As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new
Biogen to buy rare-disease drugmaker Reata in $7.3B deal
05:26pm, Friday, 28'th Jul 2023
Yahoo Finance Health Care Reporter Anjalee Khemlani reports on Biogen buying rare-disease drugmaker Reata for $7.3 billion.
S&P 500 Gains and Losses Today: Stocks Jump as Inflation Cools
05:10pm, Friday, 28'th Jul 2023
U.S. equities rallied on Friday, July 28, 2023 after a report showing inflation cooled in June, and the S&P 500 rose 1%.
